

Lucitanib dihydrochloride

Chemical Properties


CAS No. : 2108875-91-6

Formula: C₂₆H₂₇Cl₂N₃O₄

Molecular Weight: 516.42

Storage: Store at -20°C

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient inhibitor of VEGFR1-3, FGFR1-3, and PDGFR α/β , useful in metastatic breast cancer research.
Targets(IC50)	FGFR, VEGFR
In vitro	Lucitanib dihydrochloride (E-3810 dihydrochloride) has potent inhibitory effects on VEGFR and FGFR autophosphorylation and can effectively inhibit VEGF- and bFGF-induced HUVEC proliferation with IC ₅₀ values of 40 and 50 nM, respectively. It can also inhibit CSF-1R with an IC ₅₀ value of 5 nM. [1]
In vivo	Lucitanib dihydrochloride (E-3810 dihydrochloride) (20 mg/kg, oral, 7 days) treated mice, Lucitanib completely inhibited the bFGF-induced angiogenic response. Methods: Lucitanib dihydrochloride (15 mg/kg, oral, 30 days) was treated in mice bearing the MDA-MB-231 advanced breast cancer model, and tumor size was evaluated in vivo. Results: Lucitanib dihydrochloride effectively stabilized tumor growth. [3]

Solubility Information

Solubility	DMSO: 16 mg/mL (30.98 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9364 mL	9.682 mL	19.3641 mL
5 mM	0.3873 mL	1.9364 mL	3.8728 mL
10 mM	0.1936 mL	0.9682 mL	1.9364 mL
50 mM	0.0387 mL	0.1936 mL	0.3873 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Bello E, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. *Cancer Res.* 2011 Feb 15;71(4):1396-405.
- Colzani M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. *Mol Cell Proteomics.* 2014 Jun;13(6):1495-509.
- Bello E, et al. The tyrosine kinase inhibitor E-3810 combined with NSC 125973 inhibits the growth of advanced-stage triple-negative breast cancer xenografts. *Mol Cancer Ther.* 2013 Feb;12(2):131-40

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481